AI assistant
Sending…
PMV Pharmaceuticals, Inc. — Director's Dealing 2023
May 15, 2023
34350_dirs_2023-05-15_adb98c20-3b74-47a3-a342-b16adc9694b5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2023-05-12
Reporting Person: Kung Winston (COO, CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-05-12 | Employee Stock Option (right to buy) | $5.70 | A | 150000 | Acquired | 2033-05-12 | Common Stock (150000) | Direct |
Footnotes
F1: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023.
More from PMV Pharmaceuticals, Inc.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Annual Report
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 22
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 9
Interim / Quarterly Report
2025
Nov 12
Regulatory Filings
2025
Nov 12
Major Shareholding Notification
2025
Nov 12
Director's Dealing
2025
Oct 29